The vast majority of patients in both groups had sporadic benign insulinomas (84% group 1 and 75% group 2), followed by MEN1-associated benign insulinomas (13% and 12%), only 4 patients (6.6%) had malignant insulinomas (Table 1). This evidence concerns the gene MEN1 and pancreatic insulinoma.